Effect of VTCN1 on progression and metastasis of ovarian carcinoma in vitro and vivo

Biomedicine and Pharmacotherapy

Volumn 73, Issue , 2015, Pages 129-134

  Gao, Aihua ^a   Zhang, Liang ^b   Chen, Xin ^a   Chen, Ying ^a   Xu, Zhenzhen ^a   Liu, Yanan ^a   Zhu, Weipei ^a  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b Suzhou University   (China)

Author keywords

Information analysis; Ovarian carcinoma; VTCN1

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; JANUS KINASE 2; PROTEIN CDC25C; PROTEIN TYROSINE PHOSPHATASE; STAT3 PROTEIN; UNCLASSIFIED DRUG; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; VTCN1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER GROWTH; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR MODEL; TUMOR PROMOTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL SURVIVAL; DISEASE COURSE; DRUG SCREENING; METABOLISM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937807199     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.05.016     Document Type: Article

References (26)

1. Jeong H.J., Kim H.J., Lee E.H., Lee H.W., Kim M.K. Perimenopausal ovarian carcinoma patient with subclavian node metastasis proven by immunohistochemistry. J. Menopausal Med. 2014, 20:43-46.
2. Huang R., Wu D., Yuan Y., Li X., Holm R., Trope C.G., Nesland J.M., Suo Z. CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients. PloS One 2014, 9:e112209.
3. Ukita M., Nakai H., Kotani Y., Tobiume T., Koike E., Tsuji I., Suzuki A., Mandai M. Long-term survival in metastatic malignant struma ovarii treated with oral chemotherapy: a case report. Oncol. Lett. 2014, 8:2458-2462.
4. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348:203-213.
5. Milne K., Kobel M., Kalloger S.E., Barnes R.O., Gao D., Gilks C.B., Watson P.H., Nelson B.H. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FOXP3 and TIA-1 as positive prognostic factors. PloS One 2009, 4:e6412.
6. Prasad D.V., Richards S., Mai X.M., Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003, 18:863-873.
7. Choi I.H., Zhu G., Sica G.L., Strome S.E., Cheville J.C., Lau J.S., Zhu Y., Flies D.B., Tamada K., Chen L. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 2003, 171:4650-4654.
8. Quandt D., Fiedler E., Boettcher D., Marsch W., Seliger B. B7-H4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin. Cancer Res. 2011, 17:3100-3111.
9. Krambeck A.E., Thompson R.H., Dong H., Lohse C.M., Park E.S., Kuntz S.M., Leibovich B.C., Blute M.L., Cheville J.C., Kwon E.D. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10391-10396.
10. Ni D., Ma X., Li H.Z., Gao Y., Li X.T., Zhang Y., Ai Q., Zhang P., Song E.L., Huang Q.B., Fan Y., Zhang X. Downregulation of FOXO3A promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma. Clin. Cancer Res. 2014, 20:1779-1790.
11. Sadun R.E., Sachsman S.M., Chen X., Christenson K.W., Morris W.Z., Hu P., Epstein A.L. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin. Cancer Res. 2007, 13:4016-4025.
12. Isomaki P., Junttila I., Vidqvist K.L., Korpela M., Silvennoinen O. The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels. Rheumatology (Oxford) 2014, 54:1103-1113.
13. Zhang L., Zhang X., Barrisford G.W., Olumi A.F. Lexatumumab (trail-receptor 2 mab) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett. 2007, 251:146-157.
14. Qian Y., Hong B., Shen L., Wu Z., Yao H., Zhang L. B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells. Cell. Tissue Res. 2013, 353:139-151.
15. Zhang L., Wu H., Lu D., Li G., Sun C., Song H., Li J., Zhai T., Huang L., Hou C., Wang W., Zhou B., Chen S., Lu B., Zhang X. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene 2013, 32:5347-5358.
16. Arigami T., Uenosono Y., Hirata M., Hagihara T., Yanagita S., Ishigami S., Natsugoe S. Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J. Surg. Oncol. 2010, 102:748-752.
17. Chae H.D., Kim J., Shin D.Y. NF-Y binds to both G1- And G2-specific cyclin promoters; a possible role in linking CDK2/cyclin A to CDK1/cyclin B. BMB Rep. 2011, 44:553-557.
18. Bagheri-Yarmand R., Nanos-Webb A., Biernacka A., Bui T., Keyomarsi K. Cyclin E deregulation impairs mitotic progression through premature activation of CDC25C. Cancer Res. 2010, 70:5085-5095.
19. Li Z., Putzer B.M. Spliceosomal protein E regulates neoplastic cell growth by modulating expression of cyclin E/CDK2 and G2/M checkpoint proteins. J. Cell. Mol. Med. 2008, 12:2427-2438.
20. Paternot S., Colleoni B., Bisteau X., Roger P.P. The CDK4/CDK6 inhibitor pd0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes. Cell. Cycle 2014, 13:2879-2888.
21. Jaganathan H., Overstreet K., Reed E. Improving breast cancer therapy with CDK4/6 inhibitors. Clin. Breast Cancer 2014, 14:379-380.
22. Lin Y., Li D., Liang Q., Liu S., Zuo X., Li L., Sun X., Li W., Guo M., Huang Z. MIR-638 regulates differentiation and proliferation in leukemic cells by targeting cyclin-dependent kinase 2. J. Biol. Chem. 2014, 1818-1828.
23. Lee D.H., Sung K.S., Bartlett D.L., Kwon Y.T., Lee Y.J. HSP90 inhibitor NVP-AUY922 enhances trail-induced apoptosis by suppressing the JAK2-STAT3-MCL-1 signal transduction pathway in colorectal cancer cells. Cell. Signal. 2014, 293-295.
24. Liu F.Y., Safdar J., Li Z.N., Fang Q.G., Zhang X., Xu Z.F., Sun C.F. CCR7 regulates cell migration and invasion through JAK2/STAT3 in metastatic squamous cell carcinoma of the head and neck. BioMed Res. Int. 2014, 2014:415375.
25. Jorvig J.E., Chakraborty A. Zerumbone inhibits growth of hormone refractory prostate cancer cells by inhibiting JAK2/STAT3 pathway and increases paclitaxel sensitivity. Anticancer Drugs 2014, 160-166.
26. Hu Y., Hong Y., Xu Y., Liu P., Guo D.H., Chen Y. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC. Apoptosis 2014, 19:1627-1636.